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Abstract
Background: An estimated 350 adults develop severe, but potentially reversible respiratory failure in the
UK annually. Current management uses intermittent positive pressure ventilation, but barotrauma,
volutrauma and oxygen toxicity can prevent lung recovery. An alternative treatment, extracorporeal
membrane oxygenation, uses cardio-pulmonary bypass technology to temporarily provide gas exchange,
allowing ventilator settings to be reduced. While extracorporeal membrane oxygenation is proven to result
in improved outcome when compared to conventional ventilation in neonates with severe respiratory
failure, there is currently no good evidence from randomised controlled trials to compare these
managements for important clinical outcomes in adults, although evidence from case series is promising.
Methods/Design: The aim of the randomised controlled trial of Conventional ventilatory support vs
extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR) is to
assess whether, for patients with severe, but potentially reversible, respiratory failure, extracorporeal
membrane oxygenation will increase the rate of survival without severe disability ('confined to bed' and
'unable to wash or dress') by six months post-randomisation, and be cost effective from the viewpoints of
the NHS and society, compared to conventional ventilatory support. Following assent from a relative,
adults (18–65 years) with severe, but potentially reversible, respiratory failure (Murray score ≥ 3.0 or
hypercapnea with pH < 7.2) will be randomised for consideration of extracorporeal membrane oxygenation
at Glenfield Hospital, Leicester or continuing conventional care in a centre providing a high standard of
conventional treatment. The central randomisation service will minimise by type of conventional treatment
centre, age, duration of high pressure ventilation, hypoxia/hypercapnea, diagnosis and number of organs
failed, to ensure balance in key prognostic variables. Extracorporeal membrane oxygenation will not be
available for patients meeting entry criteria outside the trial. 180 patients will be recruited to have 80%
power to be able to detect a one third reduction in the primary outcome from 65% at 5% level of statistical
significance (2-sided test). Secondary outcomes include patient morbidity and health status at 6 months.
Discussion: Analysis will be based on intention to treat. A concurrent economic evaluation will also be
performed to compare the costs and outcomes of both treatments.
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Background
It is estimated that over 350 adult patients suffer from
severe, but potentially reversible, respiratory failure in the
UK each year. The mortality rate for such patients is very
high and has only improved marginally in the majority of
centres over the last 20 years[1,2] Current management
uses intermittent positive pressure ventilation (IPPV). The
airway pressures and oxygen concentrations required to
maintain adequate blood gases are often very high in
patients with severe respiratory failure, and this combina-
tion of barotrauma, volutrauma and oxygen toxicity can
prevent lung recovery. An alternative treatment, extracor-
poreal membrane oxygenation (ECMO), uses cardio-pul-
monary bypass technology to temporarily provide gas
exchange to patients with severe, but potentially reversi-
ble, respiratory failure. During ECMO, ventilator settings
can be reduced, and such 'lung-rest' allows the lungs to
recover. There is currently no good evidence from ran-
domised controlled trials (RCTs) to compare ECMO
against conventional management for important clinical
outcomes.
Patients are usually considered for ECMO when they have
such severe disease that they continue to deteriorate
despite maximal optimum 'conventional' treatment. For
the purposes of this protocol, conventional will be
defined as any treatment which relies on the patient's
lungs to provide gas exchange. Conventional treatment
may therefore include inhaled nitric oxide and prone ven-
tilation[3-5], as well as the more usual types of positive
pressure ventilation. The use of ECMO to support neonatal
patients with severe respiratory failure has been rigorously
evaluated in an RCT[6,7]. The neonatal ECMO RCT con-
vincingly demonstrated the effectiveness of ECMO in
improving patient survival without severe disability. Neo-
natal ECMO in the UK is now a supra-regional service
receiving central funding. The use of ECMO as it is cur-
rently practised in older children[8], and adults[9] is more
controversial, and has yet to be evaluated in an RCT in the
UK.
Previous studies
A review of the literature was carried out to identify all
studies relevant to adult ECMO. Only two RCTs have been
reported[1,10], both in the United States but they used
such different approaches that they have not been com-
bined as a formal meta-analysis. Each is detailed below,
followed by the recent non-experimental evidence.
An RCT of adult ECMO was conducted by the US National
Institutes of Health (NIH)[1], in the early days of extra-
corporeal support in the 1970s. Survival in both groups
was very poor (around 10%), and no difference was
shown in survival between the conventional and ECMO
treated groups. There were a number of important differ-
ences in the perfusion and ventilation techniques used
during this trial compared to those used today. Firstly,
veno-arterial (VA) rather than veno-venous (VV) per-
fusion was used, and this was thought to be responsible
for the high incidence of pulmonary micro-thrombosis
and fibrosis seen in the lungs of the ECMO patients (due
to reduced pulmonary blood flow). Secondly, patients
were anti-coagulated to such a degree that severe bleeding
occurred. Thirdly, high pressure ventilation was contin-
ued during ECMO resulting in continued barotrauma and
volutrauma[11,12]. Finally, the mean duration of ventila-
tion prior to ECMO in the NIH ECMO trial was over 9
days, whereas it is now well-recognised that after 7 days of
high pressure ventilation with high fraction of inspired
oxygen (FIO2) the lungs only have limited powers of
recovery[13].
More recently there has been an RCT of the related tech-
nique of extra-corporeal carbon dioxide removal
(ECCO2R)[10]. This showed no difference between
ECCO2R and conventional treatment. Again there were
numerous differences in the clinical and perfusion proto-
cols between this trial and those in widespread use in the
majority of centres currently[14]. Firstly, the experimental
arm of the trial used low flow ECCO2R in a group of
patients who had severe lung disease, which warranted
higher flow ECMO with full support of oxygenation and
carbon-dioxide removal. This was demonstrated by the
need to increase the airway pressure in the ECCO2R group
half-way through the study. The reliance on the patient's
lungs to provide oxygenation, especially at such high air-
way pressures, also eliminated any possibility for lung
rest. Also, despite the involvement of one of the team in
the 1970s NIH ECMO trial, in which VA ECMO was used
with very small numbers in each centre (<5), the ECCO2R
programme in this trial was not well developed prior to
the study (as the team had only provided ECCO2R to
sheep and one patient prior to starting the trial). The high
incidence of bleeding and thrombotic complications
reported in this study may attest to this inexperience. In
addition, the conventional treatment used in the trial was
Pressure Controlled Inverse Ratio Ventilation (PCIRV)
using a computer controlled algorithm. The results of this
treatment showed 44% survival compared to expected
survivals of < 20% in other similar series of patients[2].
Despite this, survival in the ECCO2R group was the same
as the 'conventional' group. The success of the PCIRV pro-
tocol in this study has led to the wide adoption of the
technique within 'conventional' ventilatory management
with survival of 66% for patients with moderate to severe
respiratory failure (mean Murray score 2.8, mean ratio
between the oxygen tension in the arterial blood and the
fraction of inspired oxygen (PaO2/FIO2) 88 mmHg)[15].
Unfortunately no other authors have been able to dupli-BMC Health Services Research 2006, 6:163 http://www.biomedcentral.com/1472-6963/6/163
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cate the PCIRV results of Morris et al. for patients with
severe progressive respiratory failure.
Because the two trials described above have little rele-
vance to the ECMO regimens used in the majority of cen-
tres worldwide, the only relevant evidence consists of
observational studies. By the nature of their design, the
information they provide is potentially biased, and must
therefore be viewed with caution.
Recent case series of patients with similar degrees of respi-
ratory failure to the eligibility criteria for the second trial
suggest survival rates without ECMO of 18% to
44%[1,10]. compared to rates of up to 66% with high
flow ECMO (including full support of oxygenation and
lung rest), provided by experienced teams principally in
the USA, UK and Germany[9,13,14].
In a cohort study of the first 50 adult patients to receive
ECMO for respiratory support at Glenfield Hospital,
Leicester, UK, patients had severe respiratory failure as
shown by the mean pre-ECMO Murray Lung Injury Score
of 3.4 (SD 0.5) and PaO2/FIO2 ratio of 65 mmHg (SD
36.9). They were referred for ECMO with severe respira-
tory failure caused by either the Acute Respiratory Distress
Syndrome (ARDS) or with pneumonia. The overall sur-
vival rate was 66%[9].
For the reasons outlined above, it is impossible to reach
firm conclusions from the above experimental and obser-
vational data regarding the clinical effectiveness or cost-
effectiveness of VV high flow ECMO for respiratory failure
in adults. The recent evidence from observational studies
does, however, suggest that ECMO could potentially be a
highly useful treatment in these patients. The case selec-
tion and treatment protocols used during ECMO are now
well defined by the international Extracorporeal Life Sup-
port Organization (ELSO), and the only team using
ECMO in adults consistently in the UK has built up clini-
cal expertise[9].
It is not possible to further define the safety and efficacy
of ECMO as a treatment without a rigorous trial. The pro-
cedure has received a Cii categorisation (safety and/or effi-
cacy not yet fully established; procedure requires a fully
controlled evaluation) from the UK Safety and Efficacy
Register of the New Interventional Procedures of the Med-
ical Royal Colleges (SERNIP). Additionally a situation of
equipoise currently exists, whereby clinicians can see the
potential benefits of ECMO, but do not have enough evi-
dence to make an informed choice as to the best treatment
for their patient.
The aim of the present trial is therefore to assess whether
for patients with severe, but potentially reversible, respira-
tory failure, ECMO will increase the rate of survival with-
out severe disability by six months post randomisation
and will be cost effective from the viewpoints of the NHS
and society, compared to conventional ventilatory sup-
port.
Methods/Design
Design
The most scientifically rigorous design to assess effects of
health interventions is that of an RCT. The design will be
similar to the highly successful UK neonatal ECMO
RCT[6] suitably adapted for the adult population. The
design will be 'pragmatic' ie it will, as far as possible, mir-
ror usual practice in the UK. The procedures are illustrated
schematically in the Figure 1 below, and detailed in the
text.
Primary hypotheses
The primary hypotheses are that, for patients with severe,
but potentially reversible, respiratory failure, ECMO:
(a) Will increase the rate of survival without severe disa-
bility by six months post-randomisation.
(b) Will be cost effective from the viewpoints of the NHS
and society, compared to conventional ventilatory sup-
port.
Inclusion criteria
i) Centres
(a) ECMO: This will be provided in the Glenfield Hospi-
tal, Leicester, which has 17 years of experience and is the
only ELSO-recognised adult ECMO centre in the UK.
(b) Conventional treatment centres (CTC): These are
either centres acknowledged by Critical Care Network
leads (where established) to provide an appropriately
high standard of conventional care for ECMO-eligible
patients, or they are units which treat ≥ 350 patients per
year, and can provide pressure controlled ventilation and
veno-venous haemofiltration.
(c) Referral hospitals (RH): In addition to the centres
described under (b) above, patients meeting ECMO entry
criteria may be entered into the trial from other hospitals,
if these hospitals are prepared to transfer the patient to a
designated CTC should the allocation be to conventional
management.
ii) Patients
Adult patients (18–65 years) with severe, but potentially
reversible respiratory failure. Severe respiratory failure will
be defined as a Murray score (appendix 1)[16] ≥3.0, or
uncompensated hypercapnea with a pH <7.20. This level
of hypercapnea was selected to reflect common intensiveBMC Health Services Research 2006, 6:163 http://www.biomedcentral.com/1472-6963/6/163
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organisation of the trial Figure 1
organisation of the trial.
Potentially eligible patients
(In CTC
1, or RH
2 prepared to refer to CTC or ECMO
3 centre)
• severe, but potentially reversible respiratory failure:
Murray score>2.5
or
uncompensated hypercapnoea with a pH <7.20
• aged 18-65 years
• duration of high pressure and/or  high FIO2 ventilation < 7 days
• no intra-cranial bleeding 
• no contra-indication to limited heparinisation
• no contra-indication to continuation of active treatment
Registration
Referring intensivist  telephones clinical advisory team 
• confirm that the patient is potentially eligible for trial
• confirm beds available (held for at least 2 hours) for
• ECMO
and
• conventional management in CTC
Randomisation
• potentially eligible patient becomes eligible (i.e. Murray score > 3)
• Assent procedure completed.
• referring intensivist telephones clinical advisory team 
• provides details or identification and prognostic factors
• clinical advisor ‘phones independent central randomisation service for random 
allocation
• clinical advisor ‘phones referring intensivist 
• reveals allocation 
• consideration of ECMO  ECMO Centre
• continued conventional treatment  in CTC
• If necessary arranges collection of patient 
• from CTC or RH to ECMO, or 
• from RH to CTC 
1 CTC = conventional treatment centre is an Intensive Care Unit providing ‘optimal’ conventional intensive care in the trial
2 RH = referral hospital is a hospital providing high dependency/intensive care, but prepared for patients in trial to be transferred to CTC or  
  ECMO centre (depending on random allocation)
3 ECMO = ECMO centre in Glenfield Hospital, Leicester.  Adult ECMO will not be available outside the trialBMC Health Services Research 2006, 6:163 http://www.biomedcentral.com/1472-6963/6/163
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care clinical practice. The Murray score must be calculated
using all 4 parameters (PaO2/FIO2, Positive End Expira-
tory Pressure (PEEP), Lung compliance and Chest X-ray
appearance). The Murray score of 3.0 is a MINIMUM entry
criterion. Since patients may deteriorate quickly and con-
ventional treatment must be optimised prior to referral
into the trial, intensivists will also have the option to dis-
cuss registration of the patient for the trial as soon as the
Murray score exceeds 2.5. If the patient then continues to
deteriorate, prior identification of available beds, and dis-
cussion of the trial with the relatives, will allow rapid ran-
domisation and trial entry.
Exclusion criteria prior to trial entry
• Duration of high pressure (> 30 cm H2O of peak inspir-
atory pressure) and/or high FIO2 (> 0.8) ventilation > 7
days.13.
• Intra-cranial bleeding.
• Any other contra-indication to limited heparinisation.
• Patients who are moribund and have any contra-indica-
tion to continuation of active treatment.
Moribund patients are those who the duty ECMO consult-
ant feels have a very low chance of meaningful survival
with ECMO treatment.
Allocation of patients
Selection bias at entry will be minimised by the proce-
dures described below and shown schematically in Figure
1. Potentially eligible patients may be entered into the
trial from any participating intensive care unit in the UK.
(If a hospital has not yet received ethics committee
approval, patients can be entered under an Emergency
Inclusion Protocol (EIP)). The referring intensivist will
contact a member of the clinical advisory team to confirm
that the patient is eligible for the trial, and that beds for
ECMO and conventional management are available.
These beds will then be 'held' for at least two hours. If
these conditions are met, the referring intensivist will dis-
cuss the trial with the patient's relative(s), give written
information, and ask for agreement to trial entry. The rel-
ative will be asked to sign the assent form indicating that
he/she believes his/her relative would not object to taking
part in the study. The intensivist will then speak to the
advisory team and, if the assent procedure has been com-
pleted, the advisor will telephone the independent central
randomisation service to register the identifying details,
and to give information about key prognostic factors.
Randomisation will then be to conventional management
or to consideration of ECMO support.
Minimization criteria will be used to ensure a balance of
key prognostic factors between groups using the following
criteria:-
Type of centre (CTC or RH)
Age (18–30, 31–45, 46–65)
Hours of high pressure and/or high FIO2 ventilation (0–
48, 49–168)
Mode of trial entry (i.e. hypoxic/hypercarbic)
Diagnostic group (pneumonia, obstetric acute respiratory
distress syndrome (ARDS), trauma including surgery
within previous 24 hours, other ARDS, and other)
Numbers of organs failed 1–2 or 3 or more, failure being
defined as an individual SOFA score for that organ of ≥
2)[17,18].
If a patient is referred into the trial when there is no inten-
sive care unit (ICU) or ECMO bed available that patient
will not be entered. If beds become available subse-
quently, the patient is still suitable and the referring inten-
sivist still wants to enter the patient then they will be
randomised in the normal fashion. The fact that these
patients were referred but were unable to be entered will
be recorded.
Referrals for trial entry from hospitals not registered as 
trial centres; Emergency Inclusion Protocol (EIP)
During the study period ECMO will not be offered outside
the framework of the trial to patients eligible for trial
entry. If, exceptionally, a UK hospital from outside the
study wishes to refer a patient, the transport team from the
ECMO centre will go to the hospital and assess the
patient. If the patient is suitable then they will call the cen-
tral randomisation service and the patient will be ran-
domised in the normal fashion. If the patient draws
conventional treatment, the ECMO team will transport
the patient to the nearest available CTC, and if selected for
ECMO they will transport the patient back to Glenfield
hospital.
Interventions
1. Conventional management
Patients randomised to conventional ventilatory support
will receive the intensive care provided as standard in one
of a number of participating CTCs. This may occasionally
involve transfer (see Transport, below) from an RH. Con-
ventional ventilatory support can include any treatment
modality thought appropriate by the patient's intensivist
(excluding ECMO or other extracorporeal techniques).
Intensivists will have full discretion to treat patients asBMC Health Services Research 2006, 6:163 http://www.biomedcentral.com/1472-6963/6/163
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they think appropriate. It will be recommended that
intensivists adopt the low volume ventilation strategy.
Adherence to this strategy is defined for the purposes of
CESAR as a plateau pressure <30 cm H2O (or if plateau
pressure is not measured the peak inspiratory pressure).
This will usually mean a tidal volume of 4–8 ml/kg body
weight as defined in the low tidal volume ventilation
strategy according to the ARDS Network group [19].
Each CTC will produce their own statement of the general
philosophy of treatment. This will be based on a pro-
forma, which will detail their approach to ventilation,
nutrition, antibiotics and other treatment issues. This pro-
forma will also collect basic data regarding the size of unit,
number of staff, cases treated per year etc.
2. ECMO
Patients randomised to ECMO will be transferred (see
Transport, below) to the ECMO centre for consideration
of ECMO support. During the trial, adult ECMO will only
be available as part of the trial. There will be no crossover
to ECMO for patients allocated to conventional manage-
ment. ECMO will be provided according to published
Glenfield Hospital treatment protocols[9]. This protocol
is very similar to those used in other ELSO recognised
adult ECMO centres [14], and is summarised below:
Veno-venous ECMO via percutaneous cannulation is used
if the patient's haemodynamic status is sufficiently stable
to make cardiac assist (via veno-arterial access) unneces-
sary. Blood is drained from the right atrium through a
cannula introduced via the right jugular or femoral veins,
and is returned via the contra-lateral femoral vein. Circuits
are designed to allow full support of gas exchange i.e.
blood flow of 120 ml/kg/min. One or two (depending on
body weight) Medos Hi-Lite 7000LT poly-methyl pentene
lungs with heat exchangers are arranged in parallel with
counter current gas flow, 100% oxygen is used as the
sweep gas. Stockert (Sorin Biomedical) roller pumps with
bladder box servo control or venous pressure servo-regu-
lation are used. Blood raceway tubing is Tygon S-65-HL
(Norton Performance Plastics). Normothermia is main-
tained. The circuit and patient are managed 24 hours per
day by a trained "ECMO Specialist" capable of performing
surveillance and emergency repairs to the circuit.
During ECMO, ventilator settings are gradually reduced to
allow lung rest, i.e. peak inspiratory pressure 20 cm H2O,
end expiratory pressure 10 cm H2O, rate 10 breaths per
minute and FIO2  30%. Anticoagulation is maintained
with heparin to keep the activated clotting time (ACT)
between 160 and 220 seconds. Patients are fed enterally
or parenterally into the circuit, as indicated. Invasive pro-
cedures are avoided to reduce the risk of haemorrhage,
and therefore any additional venous access necessary, e.g.
for haemofiltration, is achieved via the circuit. Patients are
diuresed to dry weight. Haemoglobin concentrations are
maintained at 14 g/dl, and platelet counts are kept
>100,000 per ml. Patients are weaned from ECMO and
decannulated when chest X-ray appearance and lung com-
pliance have improved, and adequate gas exchange with-
out excessive ventilation (peak pressure less than 30
cmH2O, and FIO2 less than 60%) can be demonstrated
during a 'trial-off' ECMO.
Patients developing liver failure either during or after
ECMO (defined as a serum bilirubin >200 uMol/L) are
supported with MARS (Molecular Absorbent Recirculat-
ing System, Teraklin GMBH, Rostock, Germany).
If the patient's condition alters such that ECMO is no
longer possible or appropriate then ECMO will not be ini-
tiated. However such a patient's outcome will be analysed
as part of the ECMO group (intention to treat).
3. Transport
Patients who are in a designated CTC will not need to be
transported if they are randomised to conventional man-
agement. All other trial patients will need transport,
which will be provided by a team from the ECMO centre.
If the transport team decides that it is not safe to move the
patient then s/he will remain in the original unit until s/
he is considered safe to transfer, or recovers or dies. Such
outcomes will also be analysed as part of the treatment
option to which the patient was randomised i.e. analysis
is by intention to treat.
Outcome measures
Primary
Death or severe disability at six months (defined as death
by 6 months or before discharge from hospital at any time
to end of data collection, or where the answer to the first
two questions of the Euroqol questionnaire (EQ5D) are
'confined to bed' and 'unable to wash or dress yourself').
Secondary
I) Hospital indices: duration of ventilation, use of high
frequency/oscillation/jet ventilation, use of nitric oxide,
prone positioning, use of steroids, length of ICU stay,
length of hospital stay. Some data will be recorded daily
(see "Economic issues", below). For ECMO patients only,
data will be collected on mode (VV/VA), duration of
ECMO, blood flow and sweep flow.
II) Health status 6 months after randomisation. This will
include activities of daily living, quality of life, respiratory
symptoms, cognitive psychological state and lung func-
tion. Where applicable carer strain will also be assessed.
(see also 'economic issues' below)BMC Health Services Research 2006, 6:163 http://www.biomedcentral.com/1472-6963/6/163
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III) Surviving patients will be asked to give agreement for
information to be held by the NHS Central Register if
appropriate, further funding may be requested later for
longer-term follow-up including lung function tests.
Six month follow-up
Assessment of outcome at the 6 month follow-up will be
performed by trained researchers who will interview and
examine patients in their homes. Patients and their rela-
tives will be instructed not to reveal which treatment was
used. Patients will wear a special scarf to cover the neck,
masking the presence or absence of cannulation wounds.
The assessment will include a generic measure of health
status (SF36[20]) and quality of life (Euroqol EQ5D[21]),
respiratory related quality of life (St George's Hospital
Respiratory Questionnaire[22]), psychological state (Hos-
pital Anxiety and Depression Scale[23]) and cognitive
function (Mini-Mental State Examination[24]). The inter-
view will also include specific questions on sleep (from
the Functional limitation profile[25]). Lung function will
be assessed by spirometry. Where applicable, effects on
the carer will be measured using the carer strain index[26].
If a home visit is unacceptable, patients will be offered a
telephone interview or postal questionnaire. For those
unwilling to be assessed by interview or questionnaire,
permission will be requested for information to be sought
from the patient's general practitioner.
Longer term follow-up
Further follow up will be the subject of a separate proto-
col. So that the study organisers do not lose contact with
patients should they move addresses, and also to follow
up on health status, patients are being asked to give their
agreement for their contact details to be sent to the NHS
Central Register.
Economic issues
The primary objective of the economic evaluation is to
assess incremental cost-effectiveness of ECMO in terms of
additional survival with and without disability at six
months post-randomisation. This will be done by deter-
mining the costs to health services and households,
assessing cost-effectiveness from the viewpoint of the
NHS and also from the societal viewpoint. The overall
approach will be to describe the care received by patients
in both arms of the trial, identifying use of health services
with potentially important costs or changes in household
resources.
The trial will assess the cost of treatment to the health and
social services and to patients and their families in each
treatment group. An incremental cost-effectiveness ratio
will be calculated and compared to that for similar life-
extending treatments. Information for the costs of inpa-
tient and domiciliary care will be collected using methods
adapted from the neonatal ECMO Trial [21-23]
Costs of care will be estimated by recording use of key
health care services as part of the data set for each person
in the trial, and separately estimating costs associated with
each item of health care use. Service use will be measured
as daily level of intensive care support, until discharge to
an ordinary ward. Subsequent health care costs will be
based on days of inpatient care, and use of transport, out-
patient and primary care services. Resource use after dis-
charge from hospital will be collected by questionnaire at
6 month follow up. After discharge home, trial partici-
pants will be sent an 'aide memoire' to record health serv-
ice contacts.
Societal costs will be estimated for this trial as the net total
costs to health services and to patients. Societal costs of ill-
ness can also include the costs borne by relatives and
friends of visiting, supporting and caring for the patient. It
is likely that visiting costs will differ between trial arms. A
literature review found no studies of visiting costs for
adult patients. A pilot study conducted outside the CESAR
trial has established a survey method for measuring
costs[24] and will be conducted in a sub-sample of ICUs
taking part in the trial and willing to do the additional
research, in order to describe typical visiting costs for
patients in ECMO and conventional centres.
To estimate levels of intensive care, data will be collected
within the trial about the nature and duration of organ
system support for individual patients. Data will be col-
lected at the same time as the trial from participating
intensive care centres and the ECMO centre to estimate
costs of each level of care using a standard methodology
[25,26]. Health care service use after discharge will be
derived from a questionnaire to patients at 6 months.
Patients agreeing to participate will be invited to complete
a simple diary as a memory aid to assist completion of the
6-month questionnaire. Household costs will be deter-
mined according to any changes the patients may have
experienced in household circumstances (including major
costs related to the illness and changes in economic activ-
ities).
Cost-effectiveness in terms of disability free survival and
quality-adjusted life years gained will be estimated based
on 6-month responses to the Euroqol EQ5D question-
naire.
Finally, the implications of the trial for efficient provision
of ECMO services in the UK will be considered. Until the
end of the trial, ECMO will only be available in one cen-
tre. Cost analysis will be done to assess sensitivity of cost-
effectiveness ratios to transport and local volume of serv-BMC Health Services Research 2006, 6:163 http://www.biomedcentral.com/1472-6963/6/163
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ice in the ICU and ECMO unit in order to predict the best
configuration of ECMO services, if the treatment is effec-
tive.
Data collection instruments for economic evaluation
1) For trial patients and relatives
a) Daily organ support chart to be completed by caregivers
in intensive care units for each patient in the trial
b) Patient's diary of events after discharge – to be com-
pleted and kept by patient to help answer questions at 6
months.
c) EQ5D health related quality of life questionnaire
d) Patient's and relative's costs questionnaire: versions for
survivors, and for relatives of patients who die (self com-
pleted)
2) For participating centres
a) ICU cost estimates derived from a national DH funded
study conducted by one of the trial investigators [27,28]
for each ICU (and equivalent for ECMO centre during
final year of trial)
b) Daily ward costs from participating hospitals (based on
finance data)
c) Transport costs
Other health and social care unit costs will be based on
nationally available data (e.g. Netten and Dennett,
PSSRU, University of Kent 1999 or NHS reference costs)
or special costing exercises by researchers.
Sample size
A 70% mortality in the control group is anticipated, based
on the NIH ARDS network database. Cross-referencing
with the Case Mix Programme Database, which is the
national comparative audit of patient outcomes co-ordi-
nated by the Intensive Care National Audit & Research
Centre (ICNARC) confirms that this estimated mortality
is approximately correct. The mortality of the 1,506
patients with a PaO2/FIO2 ratio of ≤ 100 mmHg in this
database was 61.6%. The mean PaO2/FIO2 ratio in the
ECMO patients was 65 mmHg with an SD of 37. Thus the
selection criteria of a Murray score of = 3.0 should success-
fully identify patients with an expected mortality of =
70%. In addition this is also the patient group that is cur-
rently receiving ECMO. Assuming a 10% risk of severe dis-
ability among survivors in both trial arms, an alpha = 0.05
(2 sided test) and beta = 0.2, a sample size of 120 patients
in each group (i.e. a total sample size of 240) would be
required to detect a reduction in the rate of primary out-
come from 73% to the 55% which is a conservative esti-
mate based on the descriptive studies of adult ECMO
already discussed. As there is some controversy about the
estimated mortality in the control group, a power calcula-
tion grid is included for a range of estimated mortalities
(Table 1), should data from the on-going trial suggest a
different level. The sample size was reviewed June 2003
when the Principal Investigators made anapplication for
an extension of funding to the Health Technology Assess-
ment Programme (HTA). In the original application, they
provided a grid showing the implications of different esti-
mates for the primary outcome in the control group and
for the size of difference. This showed, for instance, that
with a sample size of about 240 if the primary outcome
rate in the control group was about 57% or more they
would be able to detect a reduction by a third OR if the
primary outcome rate in the control group was about 73%
or more, they would be able to detect a reduction by a
quarter. If the primary outcome rate in the control group
was around 65% or more, a sample size of about 180
would allow them to detect a reduction by a third (all esti-
mates based on 5% statistical significance (2-sided test)
and 80% power). The HTA agreed an extension of recruit-
ment by which time CESAR is likely to recruit about 180
patients.
Recruitment rate
Glenfield ECMO unit treated 40–50 adults per year (prior
to 2001). In 1997, 28 hospitals referred 44 patients for
ECMO. If all 224 Intensive Care Units (ICUs) in the UK
hospitals were to refer patients for ECMO at the same rate
as the 28, a total of around 350 patients might be eligible
for trial entry in the UK per annum. It is unlikely that all
224 centres will participate, so some patients will be
treated in hospitals not participating in the trial and some
will not be asked for nor give assent for the trial. If 100
centres do wish to take part, it should be possible to
recruit sufficient patients over the recruitment period.
Statistical analysis
Type of analysis
Analysis will be by intention to treat, with sub-group anal-
yses based on the minimisation criteria at trial entry.
Frequency of analysis
An independent Data Monitoring Committee (DMC) will
review, in strict confidence, data from the trial approxi-
mately half way through the recruitment period. The
Chair of the DMC may also request additional meetings/
analyses. In the light of these data, and other evidence
from relevant studies, the DMC will inform the Steering
Committee, if in their view:
i) there is proof beyond reasonable doubt that the data
indicate that any part of the protocol under investigationBMC Health Services Research 2006, 6:163 http://www.biomedcentral.com/1472-6963/6/163
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is either clearly indicated or contra-indicated, either for all
patients or for a particular subgroup, or
ii) it is evident that no clear outcome will be obtained
with the current trial design.
Unless modification or cessation of the protocol is recom-
mended by the DMC, the Steering Committee, collabora-
tors and administrative staff (except those who supply the
confidential information) will remain ignorant of the
results of the interim analysis.
Membership of Data Monitoring Committee
Professor Sir Richard Doll (Chair until 2005), Professor
Douglas Altman (Chair from 2005), Professor Tim Evans
and Dr Duncan Macrae.
Ethical considerations
Since the patients in this trial will all be sedated and ven-
tilated the patient's next of kin will be asked to give assent
for the patient's inclusion in the trial. There will be infor-
mation booklets for the patient's relatives which will
include information about the trial, conventional treat-
ment and ECMO. This may raise some ethical issues since
strictly speaking the patient's next of kin can only assent
for treatment of an incompetent adult, and cannot give
true consent on their behalf. However, there is a duty of
care to act in the patient's best interests and apply what-
ever treatment is believed to be the most effective. Since in
this case it is not yet clear which treatment is most effec-
tive there is a larger duty of care to the community as a
whole to determine which treatment is most effective by
means of an RCT. When patients have recovered and been
discharged home they will be informed that they have
been part of a clinical trial and given a copy of the infor-
mation leaflet. During the trial period patients who would
be eligible for the trial will not be able to get ECMO in the
UK except as part of the trial.
The trial has been approved by the Trent Multicentre
Research Ethics Committee (REC) as well as relevant Local
RECs,
Ancillary studies
In addition to addressing the main aims of the study,
some collaborators may wish to conduct other more
detailed or complementary ancillary studies. The princi-
pal investigators welcome this provided that proposals are
discussed in advance with the Trial Steering Committee.
Publication policy
To safeguard the scientific integrity of the trial, data from
this study should not be presented in public or submitted
for publication without requesting comments and receiv-
ing agreement from the Trial Steering Committee. The pri-
mary results of the trial will be published by the group as
a whole although the paper will be written by a smaller
writing committee, and a table of contributors will delin-
eate individual investigators' personal contributions to
the study. The success of the trial depends on the collabo-
ration of many people.
Organisation
Principal investigators
i) Giles Peek: Will co-ordinate the activities of the collabo-
rators at all clinical centres and the project staff at Glen-
field Hospital Leicester, the Clinical Co-ordinating
Centre, will organise the clinical advisory service and in
conjunction with the clinical research fellow will promote
the trial to encourage participation of referring centres.
Will be closely involved in data analysis and a key mem-
ber of the writing committee.
ii) Diana Elbourne: Will co-ordinate activity at the London
School of Hygiene and Tropical Medicine (LSHTM), the
Data Co-ordinating Centre with particular responsibility
Table 1: POWER CALCULATION GRID
Mortality in Control Group
70% 60% 50% 45%
% of survivors severely disabled 15% 10% 5% 15% 10% 5% 15% 10% 5% 15% 10% 5%
Primary adverse outcome % 74.5 73 71.5 66 64 62 57.5 55 52.5 53.25 50.5 47.75
Relative risk 0.5 64 66 70 82 86 92 104 112 122 118 128 140
0.67 136 142 150 180 192 204 236 256 278 270 296 326
0.75 224 236 250 302 324 348 404 440 480 468 514 566
0.8 336 356 378 462 496 532 624 682 746 726 800 62
Sample size calculation for different assumptions about mortality, disability and relative risk (Beta = 0.2, Alpha = 0.05, 2 sided)BMC Health Services Research 2006, 6:163 http://www.biomedcentral.com/1472-6963/6/163
Page 10 of 13
(page number not for citation purposes)
for data collection, management and statistics. Key mem-
ber of writing committee, senior statistician.
iii) Richard Firmin: Will work closely with Giles Peek and
will be head of the clinical advisory service.
iv) Ann Truesdale: Will work closely with Diana Elbourne
as Study Co-ordinator working with staff at the LSHTM
and form part of the writing committee.
v) Miranda Mugford: Will co-ordinate the economic study
team and work closely with Clare Hibbert, and form part
of the writing committee.
vi) Hilliary Killer: Will assist in the day to day management
of the trial at the ECMO centre and will work closely with
the economic study team. Will form part of the clinical
advisory team. Will provide a nursing and technical view-
point.
vii) Clare Hibbert: Will be a member of the economic study
team with Miranda Mugford.
viii) Andy Wilson: Will co-ordinate the activities of the GP
Advisory Group and take responsibility for the follow-up
assessment at six months and form part of the writing
committee.
Trial Steering Committee
The Steering Committee will approve the main study pro-
tocol, monitor and supervise the trial towards its interim
and overall objectives, review relevant information from
other sources, consider the recommendations of the
DMC, and resolve problems brought by the trial co-ordi-
nating centres. The committee will comprise an independ-
ent chairperson, Professor David Field, independent
members, Ms Jayne Fawcett(University of York), Dr David
Goldhill (Consultant Anaesthetist, Royal National Ortho-
paedic Hospital), Mrs Silvia Holden (Cruse Bereavement
Care), Mrs Wendy Nganasurian (Patients Association),
Professor Anne Tattersfield (Professor of Respiratory Med-
icine, Nottingham City Hospital), Dr John Scott (East
Anglian Ambulance Trust) Professor Nigel Webster (Pro-
fessor of Anaesthesia and Intensive Care, Aberdeen Royal
Infirmary)as well as the members of the project manage-
ment group. This represents all the different disciplines
involved in the trial. Specialist working groups will advise
the Steering Committee.
Project Management Group (PMG)
A project management group will be established and will
be responsible for the day to day management of the trial.
The group will comprise the principal investigators and
project staff from the Clinical Co-ordinating Centre at
Leicester and the Data Co-ordinating Centre at the LSHTM
and from the health economics group based at UEA Nor-
wich and School of Health and Related Research
(ScHARR) in Sheffield. The group will meet regularly in
person and by telephone.
The responsibilities of the PMG include:
a) Establishing and monitoring recruitment of participat-
ing centres
b) Distribution and supply of data collection forms and
other appropriate documentation for the trial
c) Data collection and management
d) Data entry and cleaning
e) Data analysis
f) Organising and servicing the Data Monitoring Commit-
tee
Local co-ordination
Each participating centre will identify an intensivist as a
local co-ordinator and two intensive care nurses (one pri-
mary and one as backup).
The responsibility of the local co-ordinators will be to:
a) Ensure local research ethics approval is obtained
b) Be familiar with the trial and consider recruitment of
potentially eligible patients
c) Liaise with the Clinical Co-ordinating Centre to register
eligible patients
d) Liaise with the transport team when relevant
e) Liaise with the Data Co-ordinating Centre
f) Ensure that relevant medical and nursing staff are
informed about the trial
g) Ensure that mechanisms for recruitment are in place
h) Ensure that data collection forms are completed and
returned to the Data Co-ordinating Centre promptly and
to deal with any queries
i) Facilitate other aspects of co-ordination as relevant
j) Make data available for verification, audit and inspec-
tion purposes as necessaryBMC Health Services Research 2006, 6:163 http://www.biomedcentral.com/1472-6963/6/163
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k) Liaise with the economics team
l) Ensure that the confidentiality of all information about
trial participants is respected by all persons
Confidentiality
Patients will be identified by their trial number to ensure
confidentiality. However, as the patients in the trial will
be followed up to 6 months following randomisation, it
is essential that the team at the Data Co-ordinating Centre
has the names and addresses of the trial participants
recorded on the data collection forms in addition to the
allocated trial number. Stringent precautions will be taken
to ensure confidentiality of names and addresses at the
Data Co-ordinating Centre. The investigators and local co-
ordinators will ensure conservation of records in areas to
which access is restricted.
Discussion
The CESAR Trial should define the appropriate use of
extra-corporeal life support for adults with severe poten-
tially reversible respiratory failure. It will also determine
the cost efficacy of such treatment. CESAR will also pro-
vide profound insight into the conventional treatment of
such patients in the UK.
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CTC Conventional Treatment Centre
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DH Department of Health
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ECCO2R Extracorporeal Carbon Dioxide Removal
ECMO Extracorporeal membrane oxygenation
EIP Emergency Inclusion Protocol
ELSO Extracorporeal Life Support Organization
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FIO2 Fraction of inspired oxygen
ICNARC Intensive Care National Audit and Research Cen-
tre
ICU Intensive Care Unit
IPPV Intermittent Positive Pressure Ventilation
KPa Kilopascals
LSHTM London School of Hygiene & Tropical Medicine
MARS Molecular adsorbent recirculating system
mmHg Millimetres of mercury
NIH National Institute of Health
NSCAG National Specialist Commissioning Advisory
Group
PaO2 Partial pressure of oxygen in arterial blood
PCIRV Pressure Controlled Inverse Ratio Ventilation
PEEP Positive End Expiratory Pressure
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PIP Peak Inspiratory Pressure
RCT Randomised Controlled Trial
RH Referral Hospital
ScHARR School of Health and Related Research
SERNIP Safety & efficacy register of new interventional
procedures
SF36 Short form 36 questionnaire
SOFA Sequential Organ Failure Assessment
TV Tidal Volume
UEA University of East Anglia
UK The United Kingdon of Great Britain and Northern
Ireland
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Appendix 1: Murray score
The Murray score is a grading system for ARDS which uses
4 pieces of information graded 0–4 to give a severity index
for ARDS. The data required are:
• PaO2/FIO2 in mmHg (multiply Kpa result × 7.5): this
must be taken with the FIO2 at 1 for at least 20 minutes.
• PEEP in CMH2O
• Lung Compliance in ml/CMH2O
• Number of quadrants with infiltration seen on chest X-
ray
Patients can be registered for the trial when the Murray
Score exceeds 2.5, and are eligible to enter and be ran-
domised when it exceeds 3.0. Patients who are hypercar-
bic, but not hypoxic and therefore have a low Murray
score may enter the trial and be randomised once the arte-
rial pH falls below 7.2. The Murray score is calculated by
taking the score for each variable and dividing by 4, for the
purposes of the CESAR trial all 4 variables must be used to
calculate the score.
Score values
• PaO2/FIO2: ≥ 300 = 0, 225–299 = 1, 175–224 = 2, 100–
174 = 3, <100 = 4
• CXR: normal = 0, 1 point per quadrant infiltrated.
• PEEP: ≤ 5 = 0, 6–8 = 1, 9–11 = 2, 12–14 = 3, ≥ 15 = 4.
• Compliance (ml/cmH2O): ≥ 80 = 0, 60–79 = 1, 40–59 =
2, 20–39 = 3, and ≤ 19 = 4
The compliance may be calculated as follows: 
where TV is Tidal Volume, and PIP is Peak Inspiratory
Pressure
Example
• A patient has a PaO2 of 6.6 Kpa on 100% oxygen: To
convert KPa to mmHg = 6.6 × 7.5 = 49.5 mmHg, divide by
the FIO2 ( = 1), the PaO2/FIO2 is 49.5, as this is less than
100, score 4
• The Chest X-ray has consolidation and infiltration in 3
out of 4 quadrants score 3
• The PEEP is set at 10 CMH2O, score 2
• The Peak airway pressure is 38 CMH20, and the tidal vol-
ume is 420 ml, PIP-PEEP = 28, compliance is 420/28 = 15,
score 4
The Murray score is (to one decimal place):
4 + 3 + 2 + 4 = 13,
13/4 = 3.3
The Murray score is high enough for trial entry (>3)
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